Continuous Glucose Monitoring Prediction of Gestational Diabetes Mellitus and Perinatal Complications
Diabetes Technology & Therapeutics · 2024
DOI: 10.1089/dia.2024.0080 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Diabetes Technology & Therapeutics, 2024. Verfasst von Zoey Li und 11 weiteren Autor:innen. Beteiligte Einrichtung: Jaeb Center for Health Research, Tampa, Florida, USA. Hauptthemen laut MEDLINE: Diabetes, Gestational, Blood Glucose, Glucose Tolerance Test, Blood Glucose Self-Monitoring. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 12 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Objective
To assess the performance of continuous glucose monitoring (CGM)-measured glycemic metrics in predicting development of gestational diabetes mellitus (GDM) and select perinatal complications. Research Methods: In a prospective observational study, CGM data were collected from 760 pregnant females throughout gestation after study enrollment. GDM was diagnosed using the oral glucose tolerance test (OGTT) at 24–34 weeks of gestation. Predictive models were built using logistic and elastic net regression. Predictive performance was assessed by the area under the receiver-operating characteristic (AUROC) curve.
Results
The AUROCs of using second trimester percent time >140 mg/dL (TA140) and week 13–14 TA140 in predicting GDM were 0.81 and 0.74, respectively. The AUROCs for predicting large-for-gestational-age (LGA) births and hypertensive disorders of pregnancy (HDP) using second trimester TA140 were both 0.58. When matching the specificity of OGTT, a model using TA140 in weeks 13–14 achieved similar sensitivity to OGTT in predicting HDP (13% vs. 10%, respectively) and LGA (6% for both methods). Elastic net also demonstrated similar AUROC and diagnostic performance with no meaningful improvement by using multiple predictors.
Conclusion
CGM-measured hyperglycemic metrics such as TA140 predicted GDM with high AUROCs as early as 13–14 weeks of gestation. These metrics were also similar statistically to the OGTT at 24–34 weeks in predicting perinatal complications, although sensitivity was low for both. CGM could potentially be used as an early screening tool for elevated hyperglycemia during gestation, which could be used in addition to or instead of the OGTT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Jaeb Center for Health Research, Tampa, Florida, USA.
- Maternal Fetal Medicine Research Program, Department of Obstetrics and Gynecology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- International Diabetes Center, HealthPartners Institute, St. Louis Park, Minnesota, USA.
ORCID-Profile: Zoey Li, Roy Beck, Richard Bergenstal, Peter Calhoun
Zitieren
APA
Li, Z., Beck, R., Durnwald, C., Carlson, A., Norton, E., Bergenstal, R., Johnson, M., Dunnigan, S., Banfield, M., Krumwiede, K., Sibayan, J., & Calhoun, P. (2024). Continuous Glucose Monitoring Prediction of Gestational Diabetes Mellitus and Perinatal Complications. Diabetes Technology & Therapeutics. https://doi.org/10.1089/dia.2024.0080
Vancouver
Li Z, Beck R, Durnwald C, Carlson A, Norton E, Bergenstal R, et al. Continuous Glucose Monitoring Prediction of Gestational Diabetes Mellitus and Perinatal Complications. Diabetes Technology & Therapeutics. 2024. doi:10.1089/dia.2024.0080
BibTeX
@article{Li2024,
author = {Li, Zoey and Beck, Roy and Durnwald, Celeste and Carlson, Anders and Norton, Elizabeth and Bergenstal, Richard and Johnson, Mary and Dunnigan, Sean and Banfield, Matthew and Krumwiede, Katie and Sibayan, Judy and Calhoun, Peter},
title = {Continuous Glucose Monitoring Prediction of Gestational Diabetes Mellitus and Perinatal Complications},
journal = {Diabetes Technology & Therapeutics},
year = {2024},
doi = {10.1089/dia.2024.0080}
}
EUVIMED